

CBRN REQUIREMENTS – MEDICAL CBRN RESEARCH, DEVELOPMENT, TEST, & EVALUATION

CBRN SPRING QUARTERLY FORUM

EVENT INFORMATION

SURVEY AND PARTICIPANT LIST

You will receive via email a survey and list of participants (name and organization) after the conference. Please complete the survey to make our event even more successful in the future.

EVENT CONTACT

Krystal Heard | Associate Director, Meetings (703) 247-2558 | KHeard@NDIA.org

Carizza Gutierrez | Associate Director, Divisions (703) 247- 2599 | CGutierrez@NDIA.org

SPEAKER GIFTS

In lieu of speaker gifts, a donation is being made to the Fisher House Foundation.

HARASSMENT STATEMENT

NDIA is committed to providing a professional environment free from physical, psychological and verbal harassment. NDIA will not tolerate harassment of any kind, including but not limited to harassment based on ethnicity, religion, disability, physical appearance, gender, or sexual orientation. This policy applies to all participants and attendees at NDIA conferences, meetings and events. Harassment includes offensive gestures and verbal comments, deliberate intimidation, stalking, following, inappropriate photography and recording, sustained disruption of talks or other events, inappropriate physical contact, and unwelcome attention. Participants requested to cease harassing behavior are expected to comply immediately, and failure will serve as grounds for revoking access to the NDIA event.

EVENT CODE OF CONDUCT

NDIA's Event Code of Conduct applies to all National Defense Industrial Association (NDIA), National Training & Simulation Association (NTSA), and Women In Defense (WID) meeting-related events, whether in person at public or private facilities, online, or during virtual events. NDIA, NTSA, and WID are committed to providing a productive and welcoming environment for all participants. All participants are expected to abide by this code as well as NDIA's ethical principles and practices. Visit NDIA.org/CodeOfConduct to review the full policy.

ANTI-TRUST STATEMENT

The NDIA has a policy of strict compliance with federal and state antitrust laws. The antitrust laws prohibit competitors from engaging in actions that could result in an unreasonable restraint of trade. Consequently, NDIA members must avoid discussing certain topics when they are together at formal association membership, board, committee, and other meetings and in informal contacts with other industry members: prices, fees, rates, profit margins, or other terms or conditions of sale (including allowances, credit terms, and warranties); allocation of markets or customers or division of territories; or refusals to deal with or boycotts of suppliers, customers or other third parties, or topics that may lead participants not to deal with a particular supplier, customer or third party.

AGENDA



9:30 – 12:30 pm All times are in EST

REGISTRATION

10:00 - 10:10 am

OPENING REMARKS

BG William King, USA (Ret)

Principal/Director and Senior Fellow, Booz Allen Hamilton, Inc.

CBRN Division Chair, NDIA

10:10 - 11:00 am

KEYNOTE ADDRESS

Dr. Kevin Wingerd

Medical Programs Director, Office of the Deputy Assistant Secretary of Defense for Chemical and Biological Defense *Moderator*

Dr. Dave Hone

Chief Scientist, Joint Science and Technology Office for Chemical and Biological Defense

Stephanie Calderwell

Science & Technology Manager, Defense Threat Reduction Agency

Dr. Nate Fisher

Deputy Chief Technology Officer, Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense, Joint Project Leads - Enabling Biotechnologies

LTC Amanda Love, USA

Joint Product Manager, Joint Project Management Office Under the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND)

11:00 - 11:50 am

QUESTION & ANSWER

11:50 am - 12:00 pm

CLOSING

BG William King, USA (Ret)

Principal/Director and Senior Fellow, Booz Allen Hamilton, Inc.

CBRN Division Chair, NDIA

12:00 - 12:30 pm

NETWORKING

BIOGRAPHIES



DR. KEVIN WINGERD

Medical Program Director
Office of the Deputy Assistant Secretary of Defense for Chemical and Biological Defense

Dr. Kevin L. Wingerd is the acting Medical Research,
Development and Acquisition

Director for the Office of the Deputy Assistant Secretary of Defense for Chemical and Biological Defense. Since he assumed the role in 2022, he has overseen a dynamic portfolio that extends from early science and technology through advanced development to acquisition of medical countermeasures products for chemical and biological defense

Dr. Wingerd served as the Chief Technology Officer at the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO CBRND), Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical), headquartered at Fort Detrick, MD. Since he assumed the role in 2018, he provided oversight of a high functioning team of Department of Defense (DOD) civilians and support contractors with varied expertise in chemistry manufacturing and controls, non-clinical, and clinical development for medical countermeasures

Dr. Wingerd's support of CBRN Medical's RAIDR (Rapid Acquisition and Investigation of Drugs for Repurposing) repurposing efforts led to the acquisition and availability of medicine, equipment, and scarce COVID-19 testing supplies. He facilitated advanced development, manufacturing, and acquisition of medical solutions such as vaccines, therapeutics. and diagnostics, and provided the U.S. military forces and the nation with safe, effective, and innovative medical solutions to enhance the nation's biodefense response. Dr. Wingerd was also instrumental in the creation and development of CBRN Medical's VAMP (Vaccine Acceleration by Modular Progression) effort. VAMP is a vaccine development platform that facilitates rapid delivery of safe and effective vaccines to the Warfighter by building on lessons learned during the

COVID-19 pandemic, where investment in vaccine development against threat families (i.e. mRNA vaccines against SARS-CoV-1) led to a significantly decreased development timeline for a safe and effective SARS-CoV-2 vaccine. Leveraging interagency, industry, and academia partnership, VAMP will continue to build the Warfighter's bio-armor to protect against biological threat families. For these efforts, Dr. Wingerd was recognized as the Science and Technology Professional of the Year and awarded the 2021 Army Acquisition Executive's Excellence in Leadership Award, the David Packard Excellence in Acquisition Award in 2021, and the Defense Acquisition Workforce Award for Science and Technology Management.

Beginning in April 2014, Dr. Wingerd supported the JPM CBRN Medical as the manufacturing lead for the Joint Vaccine Acquisition Program. In this role, he assisted the vaccine managers with manufacturing, technology transfer, scale-up, process development, validation, good manufacturing practice (GMP) operations, and product development expertise. He collaborated with integrated product development teams of scientists, acquisition professionals, and regulatory support for the approval and fielding of U.S. Food and Drug Administration (FDA) approved medical countermeasures for the warfighter.

In 2005, Dr. Wingerd was hired by the BioPort Corporation (later known as Emergent BioSolutions), eventually becoming the Senior Director of Process and Analytical Development.

Dr. Wingerd graduated with honors from Trinity International University with a bachelor's degree in Biology (PreMed) and a minor in Chemistry. From 2003 to 2005, Dr. Wingerd was a postdoctoral fellow with the Neuroscience Research Institute at the University of California, Santa Barbara (UCSB). During his time at the UCSB, he published eight peer-reviewed journal articles.





DR. NATHAN A. FISHER

Deputy Chief Technology Officer
Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), Joint Project Leads - Enabling Biotechnologies

Dr. Nathan A. Fisher is the Deputy Chief Technology Officer for the Joint Program Lead for

Chemical, Biological, Radiological and Nuclear Defense (JPL-CBRND) Enabling Biotechnologies (EB) office. Dr. Fisher earned his doctoral degree from the University of Michigan Medical School while studying the connection between endospore germination and pathogenesis of Bacillus anthracis, the causative agent of anthrax disease. Prior to joining SPL-CBRND, Dr. Fisher held positions in academia, industry, and government

working to advance medical countermeasure development from concept to licensure.

Dr. Fisher is also a member of the Army Reserve with two OCONUS deployments. Most recently, he served as the USCENTCOM Microbiologist and USARCENT Public Health Emergency Officer in 2020-2021 during wave two of the COVID-19 pandemic and role out of COVID-19 vaccines in that theater.



LTC AMANDA LOVE, USA



Joint Product Manager
Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND)

LTC Amanda Love is the Joint Product Manager for the Botulinum/Plague Vaccine

Development program, Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical), a component of the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), headquartered at Aberdeen Proving Ground (APG). In this role, she is responsible for providing research, development, acquisition management, and joint service integration for products transitioning from the technology base through full life cycle management of U.S. Food and Drug Administration (FDA) approved medical countermeasure pharmaceuticals against chemical, radiological and nuclear threats. She will perform as total lifecycle systems manager, reporting to the JPM CBRN Medical, COL Matthew Clark

LTC Amanda Love was commissioned as an Army Nurse Corps officer in December 2003. Her first duty assignment was General Leonard Wood Army Community Hospital, Fort Leonard Wood, MI, where she served as a Clinical Staff Nurse on the Medical Surgical floor. LTC Love completed the Perioperative Nursing Course at Brooke Army Medical Center, Fort Sam Houston, TX, earning a new Area of Concentration (AOC) designation as a Perioperative

Nurse. Following the new AOC designation, LTC Love served as a Perioperative Staff Nurse at Dwight D. Eisenhower Army Medical Center, Fort Gordon, GA, and later as a Perioperative Assistant Clinical Nurse Officer-in-Charge at 121st Combat Support Hospital, Yongsan, South Korea.

Following completion of Captain's Career Course at Fort Sam Houston, TX, LTC Love deployed with the 10th Combat Support Hospital as the Perioperative Clinical Nurse Officer-in-Charge, Herat, Afghanistan. Upon redeployment, LTC Love was selected for the role as the Perioperative Logistics Coordinator at Brooke Army Medical Center, Fort Sam Houston, TX. During her tour at Brooke Army Medical Center, she completed Command and General Staff College, as well as a Master's degree in Health Care Systems Management with Distinction from Grantham University. While stationed at the United States Army Medical Materiel Agency, Fort Detrick, MD, LTC Love served as both the Project Manager, Medical Device Assemblage Management, and Clinical Consultant. Later assigned to Fort Hood, TX, LTC Love held several leadership positions including Executive Officer of the Warrior Transition Battalion, Clinical Nurse Officer-in-Charge, Thomas Moore Medical Home, and most recently Executive Officer, Carl R. Darnall Army Medical Center.





AN ONLINE COMMUNITY FOR DEFENSE PROFESSIONALS

Enhance Your Division and Chapter Participation Through NDIA Connect

NDIA Connect is a members-only benefit that's bustling with information, conversation, and activity stimulated by defense professionals from industry, government, and academia. Log in today to explore the platform's various functionalities and contribute to our collective mission in support of the warfighter. From anywhere and at any time, use NDIA Connect to network with colleagues, collaborate on projects, and stay connected.

Connect.NDIA.org

NDIN LEADING THE WAY IN ENGAGEMENT, NETWORKING, AND NATIONAL DEFENSE

PLAN AHEAD FOR SUCCESS | 2023 FEATURED MEETINGS, CONFERENCES, AND EVENTS



DLA SUPPLY CHAIN ALLIANCE CONFERENCE & EXHIBITION

May 3 - 4, 2023 | Richmond, VA



EMERGING TECHNOLOGIES FOR DEFENSE CONFERENCE & EXHIBITION

August 28 - 30, 2023 | Washington, DC



2023 JOINT NDIA/AIA SPRING INDUSTRIAL SECURITY CONFERENCE

May 8 - 10, 2023 | Lake Buena Vista, FL





23RD ANNUAL SCIENCE AND ENGINEERING TECHNOLOGY CONFERENCE

May 23 - 25**, 2023 | San Anztonio, TX



2023 CBRN DEFENSE CONFERENCE & EXHIBITION

July 24 - 26, 2023 | Baltimore, MD



2023 WID NATIONAL CONFERENCE

September 26, 2023 | Arlington, VA



2023 SPACE WARFIGHTING FORUM

August 17 - 18**, 2023 | Colorado Springs, CO



I/ITSEC 2023

November 27 - December 1, 2023 | Orlando, FL

*All Classified | **Partially Classified